| All Releases |
|---|
 |
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
May 1, 2007
|
18.6 KB
|
| |
TARRYTOWN, N.Y., May 01, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced positive results from the first clinical trial of its investigational drug, PRO 140, in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. Patients receiving a single 5.0 mg/kg dose of PRO 140 a...
|
|
|
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Mar 30, 2007
|
16.3 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Mar 30, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that Progenics is submitting a New Drug Application (NDA) today for marketing approval to the U.S. Food and Drug Administration (FDA) for the subcutaneous formulati...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results
Mar 15, 2007
|
15.9 KB
|
| |
TARRYTOWN, N.Y., Mar 15, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2006.
Revenues for the fourth quarter ended December 31, 2006 totaled $21.9 million compared to $2.0 million for the same quarter in 2005. For the year ended...
|
|
|
Wyeth and Progenics to Begin Clinical Testing of a New Formulation of Oral Methylnaltrexone Based on Phase 2 Findings
Mar 6, 2007
|
13.3 KB
|
| |
MADISON, N.J. and TARRYTOWN, N.Y., March 6, 2007 /PRNewswire via COMTEX News Network/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that Wyeth is beginning clinical testing this month of a new formulation of oral methylnaltrexone for the treatment of opioid-induced cons...
|
|
|
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Jan 8, 2007
|
11.5 KB
|
| |
TARRYTOWN, N.Y., Jan 08, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it has named Walter M. Capone, to the newly created position of Vice President, Commercial Development and Operations. Additionally, Nicole S. Williams has been appointed to the Company's Board of Directors.
Mr. Capone joins Prog...
|
|
|
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Dec 20, 2006
|
14.4 KB
|
| |
MADISON, N.J. and TARRYTOWN, N.Y., Dec 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of the second of two global, pivotal phase 3 clinical trials to evaluate the safety and efficacy of intravenous me...
|
|
|
Progenics Achieves Enrollment Target in Clinical Trial of HIV Entry Inhibitor PRO 140
Dec 14, 2006
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Dec 14, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has completed enrollment and dosing in a phase 1b clinical trial of PRO 140, a new investigational HIV therapy. PRO 140 is a humanized monoclonal antibody that binds CCR5, a principal portal used by HIV to enter cells and a promis...
|
|
|
Progenics Pharmaceuticals Reports Third Quarter 2006 Results
Nov 9, 2006
|
13.4 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its results of operations for the third quarter, and the first nine months, ended September 30, 2006.
Revenues for the third quarter ended September 30, 2006 totaled $17.8 million compared to $2.8 million for the same quarter in 2005....
|
|
|
Progenics Earns $5 Million from Wyeth for Achieving Methylnaltrexone Milestone
Oct 25, 2006
|
11.5 KB
|
| |
TARRYTOWN, N.Y., Oct 25, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has earned a $5 million payment from Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). This first milestone payment under the companies' collaborative agreement was triggered by Progenics' start of a phase 3 clinical trial o...
|
|
|
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Sep 20, 2006
|
14.9 KB
|
| |
TARRYTOWN, N.Y. & MADISON, N.J., Sep 20, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc., (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the first of two global, pivotal, phase 3 clinical trials to evaluate the safety and efficacy of intravenous methylnaltrexone for the treatment...
|
|
|
Wyeth and Progenics Pharmaceuticals Announce Initiation of Phase 2 Clinical Trial of Oral Methylnaltrexone
Aug 22, 2006
|
12.7 KB
|
| |
MADISON, N.J. and TARRYTOWN, N.Y., Aug 22, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 2 clinical trial to evaluate once-daily dosing of oral methylnaltrexone. This trial is designed to iden...
|
|
|
Progenics Pharmaceuticals Reports Second Quarter 2006 Results
Aug 8, 2006
|
13.0 KB
|
| |
TARRYTOWN, N.Y., Aug 08, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its results of operations for the second quarter ended June 30, 2006 and the first half of 2006.
Revenues for the second quarter ended June 30, 2006 totaled $19.1 million compared to $2.1 million for the same quarter in 2005. For the ...
|
|
|
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Jul 17, 2006
|
12.3 KB
|
| |
MADISON, N.J. & TARRYTOWN, N.Y., Jul 17, 2006 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that the intravenous form of methylnaltrexone being investigated for the treatment of postoperative ileus, a serious impairment of gastrointestinal function that ...
|
|
|
CORRECTING and REPLACING Wyeth and Progenics Pharmaceuticals Announce Development Plans for Methylnaltrexone
Jun 6, 2006
|
78.3 KB
|
| |
MADISON, N.J. & TARRYTOWN, N.Y., Jun 06, 2006 (BUSINESS WIRE) -- Headline of release should read: Wyeth and Progenics Pharmaceuticals Announce Development Plans for Methylnaltrexone (sted Methylnalatrexone) The corrected release reads:
WYETH AND PROGENICS PHARMACEUTICALS ANNOUNCE DEVELOPMENT PLANS FOR METHYLNALTREXONE
Treatment Platform ...
|
|
|
Progenics Broadens Collaboration with Seattle Genetics for Prostate Cancer Therapy; Positive Preclinical Findings on PSMA Antibody-Drug Conjugate Published in Clinical Cancer Research Journal
May 25, 2006
|
72.4 KB
|
| |
TARRYTOWN, N.Y., May 25, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced the expansion of its collaboration with Seattle Genetics, Inc. (NASDAQ: SGEN) to include activities intended to accelerate the manufacture and development of Progenics' prostate-specific membrane antigen (PSMA) antibody-drug conjugate (A...
|
|
|
Positive Results from Phase 3 Clinical Study of Methylnaltrexone Treatment for Opioid-Induced Constipation Presented at Digestive Disease Week Conference
May 23, 2006
|
72.3 KB
|
| |
LOS ANGELES, May 23, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that a late-breaking oral presentation of phase 3 clinical trial results for methylnaltrexone was made today at the Digestive Disease Week (DDW) conference in Los Angeles, CA.
The res...
|
|
|
Progenics Pharmaceuticals Reports First Quarter 2006 Results; Loss Narrows as MNTX Development Costs Are Reimbursed and a Portion of the Upfront Payment from Wyeth is Recognized as Revenue
May 9, 2006
|
86.0 KB
|
| |
TARRYTOWN, N.Y., May 09, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2006. Revenues for the quarter ended March 31, 2006 totaled $11.0 million compared to revenues of $2.6 million for the same period in 2005. Revenues for the quarter prima...
|
|
|
Progenics Pharmaceuticals Acquires Full Ownership of Prostate Cancer Joint Venture
Apr 24, 2006
|
53.7 KB
|
| |
TARRYTOWN, N.Y., Apr 24, 2006 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has acquired complete ownership and control of PSMA Development Company LLC (PDC), by purchasing Cytogen Corporation's (Nasdaq: CYTO) interest in the joint venture which is developing in vivo cancer immunotherapies based on prosta...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results
Mar 15, 2006
|
84.9 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--March 15, 2006--Progenics
Pharmaceuticals, Inc., (NASDAQ: PGNX) today announced its results of
operations for the fourth quarter and year ended December 31, 2005.
Revenues for the fourth quarter ended December 31, 2005 totaled
$2.0 million compared to $3.3 million for the same quarter in 2004.
Fo...
|
|
|
Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation
Feb 22, 2006
|
71.9 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 22, 2006--Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that PRO 140 has
been designated a fast track product by the U.S. Food and Drug
Administration (FDA) for the treatment of human immunodeficiency virus
(HIV) infection. The FDA Fast Track Development Program facilitates
develop...
|
|
|
